In this interview, Steven Facer, Senior Vice President of Global Sales and Marketing at Adare Pharma Solutions, outlines the essential elements of successful CDMO partnerships in today’s fast-paced, complex pharmaceutical environment. With shrinking timelines and rising development challenges, sponsors increasingly rely on CDMOs that offer deep oral solid dose expertise, integrated capabilities, and flexible, customer-focused support.
Facer emphasizes that selecting the right CDMO can accelerate development, reduce risk, and enhance long-term success. Adare’s approach is grounded in end-to-end services, from formulation to commercial packaging, and bolstered by a global network of manufacturing facilities in the U.S. and Europe. This enables Adare to help sponsors navigate global supply chain disruptions, execute smooth tech transfers, and adapt to market demands.
A key differentiator is Adare’s investment in advanced technologies like 3D screen printing, which allows for the scalable production of complex, personalized dosage forms with multiple release profiles and APIs. This innovation aligns with the growing demand for precision therapies and flexible dosing options.
Facer also discusses the importance of maintaining a harmonized global quality system and a customer-centric culture. At Adare, dedicated project managers ensure seamless communication and alignment across development, manufacturing, quality, and regulatory teams. By fostering long-term relationships and anticipating sponsor needs, Adare helps pharmaceutical companies bring products to market faster and more efficiently.
Ultimately, Adare’s success stems from listening to its customers, delivering tailored solutions, and evolving capabilities to support the dynamic needs of modern drug development.
